Showing 1 - 20 results of 43,159 for search '(( 50 ((ms decrease) OR (a decrease)) ) OR ((( 16 we decrease ) OR ( 50 _ decrease ))))*', query time: 0.92s Refine Results
  1. 1
  2. 2

    SLE decreases risk for hormonal cancers. by Deborah K. Johnson (10001156)

    Published 2021
    “…(b) Prostate cancer incidence in male SLE cohort is significantly decreased by SLE status (OR 0.23, 95% CI 0.089, 0.50, p = 0.0053).…”
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Acute myocardial infarction changes bone marrow cell composition and decreases endothelial differentiation capability. by Ming-Yao Chang (700415)

    Published 2015
    “…<p><b>(A)</b> CD14 positive cells increased at day 1 post-MI while the CD16 positive cell decreased at day 4 and day 7 after infarction in <b>B</b> with n ≥3 per groups. …”
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    DART-ID decreases missing datapoints across runs. by Albert Tian Chen (6900215)

    Published 2019
    “…Only peptides seen in >50% of experiments are included. (<b>b</b>) Decrease in missing data across all runs after applying DART-ID, for SCoPE-MS and the two bulk sets from <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1007082#pcbi.1007082.g004" target="_blank">Fig 4</a> at 1% FDR. …”
  17. 17
  18. 18

    BMT decreases HFD-induced weight gain associated with decreased preadipocyte number and insulin secretion by Saeed Katiraei (3956147)

    Published 2017
    “…The application of BMT in obesity research is hampered by the significant reduction in high-fat diet (HFD)-induced obesity. We set out to characterize metabolic tissues that may be affected by the BMT procedure and impair the HFD-induced response. …”
  19. 19
  20. 20

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”